Advances in homology directed genetic engineering of human pluripotent and adult stem cells by Ramamoorthi, Kalpith et al.
Santa Clara University
Scholar Commons
Bioengineering School of Engineering
10-26-2013
Advances in homology directed genetic
engineering of human pluripotent and adult stem
cells
Kalpith Ramamoorthi
Donald Curtis
Prashanth Asuri
Santa Clara University, asurip@scu.edu
Follow this and additional works at: http://scholarcommons.scu.edu/bio_eng
This Article is brought to you for free and open access by the School of Engineering at Scholar Commons. It has been accepted for inclusion in
Bioengineering by an authorized administrator of Scholar Commons. For more information, please contact rscroggin@scu.edu.
Recommended Citation
Ramamoorthi K, Curtis D, Asuri P. Advances in homology directed genetic engineering of human pluripotent and adult stem cells.
World J Stem Cells 2013; 5(4): 98-105 Available from: URL: http://www.wjgnet.com/1948-0210/full/v5/i4/98.htm
DOI: http://dx.doi.org/10.4252/wjsc.v5.i4.98
Advances in homology directed genetic engineering of 
human pluripotent and adult stem cells
Kalpith Ramamoorthi, Donald Curtis, Prashanth Asuri
Kalpith Ramamoorthi, Donald Curtis, Prashanth Asuri, 
Department of Bioengineering, Santa Clara University, Santa 
Clara, CA 95053, United States
Author contributions: All authors have contributed to this article.
Correspondence to: Prashanth Asuri, PhD, Department of 
Bioengineering, Santa Clara University, 500 El Camino Real, 
Santa Clara, CA 95053, United States. asurip@scu.edu
Telephone: +1-408-5513005  Fax: +1-408-5545474
Received: August 15, 2013     Revised: September 6, 2013
Accepted: September 14, 2013
Published online: October 26, 2013
Abstract
The ability to introduce precise genomic modifications 
in human cells has profound implications for both ba-
sic and applied research in stem cells, ranging from 
identification of genes regulating stem cell self-renewal 
and multilineage differentiation to therapeutic gene 
correction and creation of in vitro  models of human 
diseases. However, the overall efficiency of this process 
is challenged by several factors including inefficient 
gene delivery into stem cells and low rates of homol-
ogy directed site-specific targeting. Recent studies re-
port the development of novel techniques to improve 
gene targeting efficiencies in human stem cells; these 
methods include molecular engineering of viral vectors 
to efficiently deliver episomal genetic sequences that 
can participate in homology directed targeting, as well 
as the design of synthetic proteins that can introduce 
double-stranded breaks in DNA to initiate such recom-
bination events. This review focuses on the potential 
of these new technologies to precisely alter the human 
stem cell genome and also highlights the possibilities 
offered by the combination of these complementary 
strategies. 
© 2013 Baishideng. All rights reserved.
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Core tip: This manuscript focuses on the development of 
novel technologies to precisely alter the human stem cell 
genome and highlights their implications for both basic 
and applied stem cell research. Specifically, we discuss 
the development of two main technologies: molecular 
engineering of viral vectors and design of artificial en-
donucleases. We also discuss the merits of combining 
these complementary approaches and suggest other 
possible strategies that could be explored to further im-
prove genetic engineering of human stem cells.
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INTRODUCTION
Gene targeting via homologous recombination (HR) 
presents a precise way to manipulate the mammalian ge-
nome at specific loci. Such legitimate site-directed gene 
targeting requires homology between the donor DNA 
and the endogenous chromosome, and results in the sub-
stitution of  DNA between the homologous donor and 
the endogenous chromosomal sequence (Figure 1). Cre-
ating or correcting specific mutations in human stem cells 
provides great utility in stem cell research; for example, 
gene knock-in and knockout studies can be carried out to 
identify and study specific genes expressed and involved 
in stem cell fate decisions, as well as to create lineage-spe-
cific reporter cell lines to screen for signaling pathways in 
vitro and to monitor differentiation and proliferation of  
stem cells following transplantation in vivo[1-5]. Targeted 
gene mutations also facilitate the generation of  models 
to investigate human developmental diseases and screen 
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for potential therapies[6]. Therefore, mediating efficient 
gene targeting in human stem cells impacts the future ap-
plication of  these cells in tissue engineering, regenerative 
medicine, and high-throughput drug discovery and toxi-
cology. Current strategies to manipulate the mammalian 
cell genome are mostly viral-based; several viral gene de-
livery systems, including adenovirus, retrovirus, and len-
tivirus provide high transduction efficiencies, integration 
into the host cell genome, and high levels of  gene expres-
sion[7-9]. Lentiviral vectors in particular are highly efficient 
and result in stable, long-term transgene expression with-
out gene silencing and have been extensively employed in 
studies of  human stem cells[9]. However, viral approaches 
are often complicated by random vector integration into 
the host genome that results in genomic instability lead-
ing to increased risk of  oncogenesis, a major concern for 
downstream clinical applications[10,11]. In contrast, non-
viral methods, such as encapsulation of  DNA by lipid 
or cationic polymer vesicles and naked DNA delivery by 
either physical (electroporation) or chemical methods, 
deliver DNA episomally and therefore can in principle 
avoid insertional mutagenesis due to random integra-
tion; however, their application for gene targeting is often 
restricted by inefficient delivery and by the inability to 
provide sustained gene expression[12,13]. Thus, despite the 
enormous potential of  genetically modified stem cells 
in basic and translational research, low rates of  targeted 
gene modifications in human stem cells have limited the 
realization of  these applications. 
This review focuses on recent advances in gene tar-
geting techniques, with particular emphasis on technolo-
gies that significantly enhance the rates of  homology 
directed genetic engineering of  human pluripotent and 
adult stem cells. These advances open up a range of  
experimental and therapeutic possibilities, including in-
struction of  stem cell differentiation into therapeutically 
relevant cells and development of  stem cell-based disease 
models for drug development. 
BARRIERS TO GENE TARGETING
Low efficiencies of  gene targeting can result from a com-
bination of  extracellular and intracellular barriers and in-
creasing our understanding of  the contributions of  these 
barriers to gene targeting, as well as strategies to success-
fully overcome them will benefit the design of  efficient 
vectors for enhanced gene transfer and targeting. The 
series of  barriers that challenge the progress of  the gene 
targeting constructs to the cell nucleus include inefficient 
transport across the cell membrane and the nuclear en-
velope, as well as diffusional and metabolic barriers of  
the cytoplasm that reduce the amount of  intact donor 
DNA constructs that reach the nuclear envelope (Figure 
2)[13-16]. Inside the nucleus, exogenous DNA can integrate 
at predetermined sites via homologous recombination 
into the genome, although in general the rates of  random 
integration are far greater than those of  homologous in-
tegration; this low spontaneous frequency of  site-specific 
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Figure 1  Random and homologous integration. Introduction of a foreign gene into mammalian cells can either result in its random integration into the endogenous 
chromosomal DNA, or site-specific integration at the desired location dictated by the homology between the donor DNA and the endogenous target locus.
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Figure 2  Barriers to gene targeting. The dif-
ferent barriers that gene delivery vectors must 
overcome for successful gene targeting include 
cell binding and internalization, intracellular traf-
ficking and endosomal escape, translocation 
through the nuclear envelope, and efficient site-
specific integration.
integration necessitates identification of  the small frac-
tion of  cells undergoing homologous integration by a 
combination of  positive and negative selection, which 
require considerable time and expertise[17,18]. 
Recent years have witnessed the emergence of  two 
main strategies to overcome these barriers: (1) molecular 
engineering of  viral vectors to improve their safety and 
efficiency and (2) artificial endonucleases that introduce 
site-specific DNA double-stranded breaks to stimulate 
targeted integration. Here we will review the use of  these 
novel technologies to carry out homology directed gene 
knock-outs, knock-ins, and corrections in human stem 
cells and their potential for advancing basic and applied 
stem cell research.
MOLECULAR ENGINEERING OF VIRAL 
VECTORS
Lentivirus-based gene delivery vectors have been widely 
examined for in vivo and in vitro applications owing to 
their inherent advantages - specifically, they can efficiently 
transduce both dividing and non-dividing cells, can be 
pseudotyped to optimize tropism to a specific cell or 
tissue of  interest, can transduce both dividing and non-
dividing cells, and do not induce significant immune re-
sponses[19,20]. However, their broad applicability has been 
limited by the risk of  mutagenesis associated with ran-
dom vector integration into the target genome. Recently, 
it has been demonstrated that the random insertion event 
can be prevented by simply introducing mutations in the 
integrase protein of  the virus that facilitates viral genome 
integration[21]. Such integrase-deficient lentiviral vectors 
(IDLV) represent new avenues for targeted genetic engi-
neering of  human stem cells due to their ability to deliver 
episomal donor DNA for homologous recombination, 
while retaining their unique ability to efficiently infect 
both dividing and non-dividing cells. For example, IDLV 
have been shown to efficiently transduce both dividing 
(human embryonic kidney 293) and non-dividing cells 
(primary neurons and astrocytes) in vitro. And the trans-
gene expression, monitored using GFP fluorescence, 
was transient in dividing cells and stable in non-dividing 
cells, consistent with transcription from episomal genetic 
sequences. Moreover, residual integration activity stud-
ies confirmed significantly reduced occurrence (102-103 
fold lower) of  integration events compared to wild-type 
lentiviral vectors. IDLVs have also been used to provide 
clinical benefits for patients with X-Linked adrenoleuko-
dystrophy (ALD)[22]. ALD is caused by a mutation in the 
ABCD1 gene encoding for the ALD protein, which leads 
to accumulation of  abnormally high levels of  very long 
chain fatty acids (VLCFAs) causing the adrenal cortex 
and the myelin membranes that surround nerves to cease 
functioning. A lentiviral vector encoding the wild-type 
ABCD1 was introduced into CD34+ cells obtained from 
ALD patients and the transformed cells were then re-
infused into patients. Quantitative analysis using RT-PCR 
showed that the expression of  ABCD1 transgene was 
four- to five-fold higher than the endogenous mutated 
ABCD1 gene. Furthermore, after 20-24 mo, the VLCFA 
levels in patients decreased by up to 39%. Finally, IDLVs 
encoding for cytokines have been used to induce human 
monocytes to differentiate into dendritic cells and the 
resulting induced dendritic cells were functional and ca-
pable of  stimulating multivalent immune responses in vi-
tro and in vivo[23]. In addition to developing non-integrative 
vectors, researchers are also pursuing approaches to en-
gineer safer viral vectors by overriding the intrinsic pref-
erences of  viral genomic integration for transcriptional 
start sites (TSS); for example, Lim et al[24] discovered that 
the addition of  DNA binding domains at key sites within 
retroviral vectors shifted their integration patterns toward 
regions where TSS are relatively rare. Another approach 
is the incorporation of  Cre recombinase into lentiviral 
vectors for directed gene targeting[25]. Although this ap-
proach is limited by Cre’s specificity for loxP sites that are 
not native to the mammalian genome, researchers have 
reported the presence of  pseudo loxP sites in the human 
genome that can be targeted by either wild-type Cre or 
Cre variants[26]. 
Recently, adeno-associated virus (AAV) based gene 
targeting vectors have attracted significant attention as an 
alternative to the more commonly used lentivirus- and 
adenovirus-based vectors, mainly because of  their ability 
to deliver transgenes in episomal form and mediate long-
term gene expression in dividing and non-dividing cells 
of  numerous human tissues[27]. Additionally, it has been 
demonstrated that AAV vectors can also be used to in-
troduce site-specific genetic modifications in human cells 
with high efficiencies (up to 1%) that are 103-104-fold 
higher than plasmid constructs delivered using elec-
troporation[28]. There is evidence supporting that AAV 
genome’s inverted terminal repeats facilitate its stable 
integration into the host cell genome using the RAD51/
RAD54 pathway of  HR in eukaryotes[29]. The ability of  
AAV to introduce targeted genetic modifications in hu-
man cells has been exploited in a variety of  applications 
including the creation of  isogenic (knock-in) cells that 
could be used to study cancer genes in a high-throughput 
manner. Di Nicolantonio et al[30] recently used this ap-
proach to evaluate the effect of  drugs on isogenic breast 
epithelial cells expressing wild-type and mutant alleles 
of  BRAF, KRAS, PIK3CA, and EGFR genes previously 
implicated in oncogenic pathways. Erlotinib and gefitinib 
(EGFR tyrosine kinase inhibitors) were shown to prevent 
cell proliferation and induce apoptosis selectively in cells 
carrying the EGFR delE746-A750 deletion, while the 
cells with KRAS or BRAF mutations were more resistant 
to these drugs.  
AAV-based vectors have also been evaluated for their 
ability to perform HR mediated gene targeting in hu-
man stem cells, and these studies revealed that the gene-
targeting frequency for AAV-based vectors was about 1 
× 10-5; the low frequencies observed in this study could 
be attributed to low efficiency of  naturally occurring 
AAV variants in mediating gene delivery to human stem 
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cytoplasm to the nucleus) following cellular uptake. Pre-
vious studies have shown that inhibition of  the EGFR-
PTK mediated phosphorylation of  AAV capsid proteins 
at tyrosine residues results in decreased ubiquitination of  
AAV capsids and their proteasome-mediated degrada-
tion, thereby enabling nuclear transport of  AAV vectors 
and improved gene delivery to the cell nucleus[38]. Based 
on these results, Zhong et al[39] hypothesized that substitu-
tion of  surface-exposed tyrosine residues on AAV cap-
sids may lead to the design of  AAV vectors that facilitate 
efficient delivery of  genes to the nucleus of  target cells 
at lower doses. Consistent with this hypothesis, they ob-
served that site-directed mutagenesis of  surface-exposed 
tyrosine residues significantly improve the transduction 
efficiency of  AAV vectors (about 10-fold increase) in hu-
man epithelial cells in vitro. It has also been demonstrated 
that tyrosine mutant AAV vectors display enhanced gene 
delivery efficiencies in vivo when compared to wild-type 
AAV vectors[40]. Although further investigation is war-
ranted, such enhanced AAV vectors engineered through 
rational design to avoid cytoplasmic degradation could 
also potentially enhance the efficiencies of  AAV-mediated 
gene targeting in human stem cells.
INTRODUCTION OF SITE-SPECIFIC DNA 
DOUBLE-STRANDED BREAKS
It has been previously demonstrated that the rate of  
homologous recombination with donor DNA can be 
enhanced by the introduction of  double-stranded breaks 
(DSBs) in the mammalian genome using nucleases such 
as I-SceI[41]. Building upon this important prior work, sci-
entists have recently developed highly specific nucleases 
such as zinc finger nucleases that can be in principle engi-
neered to target and introduce DNA DSBs at any site in 
the genome and thus facilitate targeted modifications of  
endogenous genes. Zinc finger nucleases (ZFNs) are syn-
thetic proteins composed of  a DNA-binding domain that 
can be engineered to target desired DNA sequences fused 
to a non-specific endonuclease domain usually derived 
from the FokI enzyme[42]. The zinc finger binding domain 
contains several amino acids stabilized by a zinc ion; such 
zinc finger domains used in tandem can guide the non-
specific DNA cleaving domain to create a double-strand 
cells[31,32]. Directed evolution approaches, therefore, have 
been applied to rapidly engineer AAV mutants with the 
capacity for high efficiency gene delivery to human adult 
and pluripotent stem cells. Unlike the more deliberate 
rational design approaches where the virus is modified 
based on an understanding of  the mechanistic conse-
quences of  a particular set of  changes, directed evolution 
is a rapid, high-throughput selection approach to create 
and isolate novel virus mutants with specific properties 
of  interest through appropriate selection pressures from 
millions of  genetic variants. Central to the approach is 
the highly evolvable AAV capsid that determines the viral 
infectivity and tropism. This approach employs iterative 
rounds of  genetic diversification, either via error-prone 
PCR or DNA shuffling and artificial selection pressures 
to incrementally alter the desired phenotypes. For ex-
ample, it has been demonstrated that directed evolution 
of  AAV capsids can be used to select variants with the 
ability to evade antibody neutralization and deliver genes 
more efficiently that wild-type AAV[33] (Figure 3). Other 
successful examples include the isolation of  AAV vari-
ants with altered receptor binding and cell tropism in vitro 
and in vivo, and enhanced gene delivery[34,35]. Using this 
approach, researchers have recently created a novel AAV 
variant - AAV r3.45 that mediates efficient gene delivery 
to both murine (infection efficiency > 40%) and human 
(infection efficiency > 30%) neural stem cells (NSCs) 
when compared to naturally occurring AAV variants 
(infection efficiency < 1%)[36]. More importantly, this 
increase in gene delivery efficiency was accompanied by 
up to 10-fold enhancement in the ability to repair single-
base pair mutations in rat NSCs, relative to naturally 
occurring AAV. In a related study, researchers have also 
demonstrated the ability of  directed evolution approach-
es to isolate a new AAV variant, AAV 1.9 that exhibited 
enhanced gene delivery to both human embryonic stem 
cells (ESCs) and induced pluripotent stem cells (iPSCs) 
(infection efficiencies: 40%-50%) that was accompanied 
by a corresponding increase in AAV 1.9’s capacity for 
gene targeting, with efficiencies as high as 0.12%, in hu-
man ESCs and iPSCs[37].
Another strategy that has been used to improve the 
ability of  AAV vectors to deliver genes to human cells 
is to facilitate AAV’s intracellular trafficking (from the 
Figure 3  Schematic of steps in the directed evolution of 
adeno-associated virus. The wild-type adeno-associated 
virus (AAV) cap genes are mutated to create large genetic 
libraries (1) and the mutant cap genes are packaged to gen-
erate libraries of AAV particles (2), with each AAV composed 
of a variant capsid surrounding a viral genome encoding 
that capsid. The resulting AAV libraries can be subjected to 
appropriate selective pressures (3) to isolate vectors with 
modified capsids that facilitate the AAV variants to efficiently 
surmount these pressures (4). Examples include isolation of 
AAV variants with the ability to evade neutralizing antibod-
ies, altered receptor binding and cell tropism, and enhanced 
gene delivery. Successful AAV variants are amplified and 
recovered (6), or can be subjected to additional rounds of 
mutagenesis and selection (5). Adapted from Maheshri et 
al[33] and Bartel et al[35].
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break at a specific target site within a genome. The cleav-
age domain must dimerize in order to become active and 
cleave DNA, thus two ZFN subunits are assembled as 
heterodimers at the target cleavage site (Figure 4A). Such 
double-strand breaks are typically repaired by two cellular 
repair pathways: non-homologous end joining (NHEJ) 
and homologous recombination (Figure 4B and C). 
NHEJ is the major DNA DSB repair pathway in eu-
karyotic cells and it repairs DNA breaks by direct ligation 
without the need for a homologous template. Typically, 
this repair pathway does not create mutations if  the two 
ends are compatible; however, when the two ends are 
not compatible then NHEJ is prone to cause mutations 
(insertion or deletion), thereby knocking out the gene 
(Figure 4C). The ability of  ZFNs to facilitate targeted 
gene knockouts has been recently exploited to disrupt the 
CCR5 gene in human CD4+ T-cells[43]. CCR5 is a co-re-
ceptor used by the human immunodeficiency virus (HIV) 
to infect cells of  the immune system; the disrupted gene 
produces malformed CCR5 proteins and confers resis-
tance to HIV infection. The safety and efficacy of  T-cells 
modified by ZFNs targeting the CCR5 gene are currently 
being evaluated in a clinical trial (ClinicalTrials.gov identi-
fier NCT00842634). Continuing to build upon this work, 
researchers have also used ZFNs to disrupt the CCR5 
gene in human hematopoietic stem/progenitor cells[44], 
and this approach may lead to providing individuals with 
a self-renewable and potentially lifelong source of  HIV-
resistant immune cells. 
In contrast, DNA repair using the HR pathway relies 
on a homologous DNA sequence that promotes ac-
curate repair of  DSBs (Figure 4B). In addition to gene 
knockout, this approach also allows precise correction 
of  mutated or dysfunctional human genes to restore 
normal function[45,46] and targeted gene addition into a 
specified location in the human cellular genome[47]. Cor-
rection of  endogenous genes in human cells was first 
demonstrated in a study using ZFNs that recognize an 
X-linked severe combined immune deficiency mutation 
in the IL2Rγ gene, with targeting frequencies as high 
as 5.3% in human CD4+ T-cells[45]. Recently, it has also 
been demonstrated that ZFNs can enable targeted gene 
correction in human embryonic and induced pluripotent 
stem cells; in this study, the authors demonstrate gene 
targeting efficiencies of  up to 0.24% when the cells were 
cotransfected with donor DNA and ZFNs specific to 
the target site, a > 2400-fold increase in the gene cor-
rection efficiencies when compared to without ZFNs (< 
10-6). This ability of  ZFNs to facilitate site-specific gene 
corrections has immense potential to facilitate the gen-
eration of  genetically corrected, patient-derived cells for 
autologous transplantation therapies. Recently, Joung and 
coworkers demonstrated in situ correction of  the disease 
causing mutation in iPSCs derived from sickle cell ane-
mia patients[48]. Finally, homology directed gene addition 
has also been demonstrated in human pluripotent stem 
cells; ZFNs can be used to target both expressed (OCT4) 
and non-expressed (PITX3) genes in human pluripotent 
stem cells and knock-in reporter genes (eGFP) to create 
reporter cell lines[47]. ZFNs can also be used to knock-in 
mutations in the mammalian genome to generate in vitro 
models of  human disease. For example, Soldner et al[49] 
reported the use of  ZFNs to develop genetically defined 
human in vitro models of  Parkinson’s disease (PD) by in-
troducing PD-causing α-synuclein mutations into hESCs. 
Despite the huge therapeutic potential for ZFNs there 
are complications with toxicity and specificity. Extensive 
testing of  several variants of  ZFNs is required to find the 
right ZFN pair to minimize off-target binding, therefore 
making the process both time-consuming and expensive. 
Fok1
Fok1
Cleavage 
domain
Cleavage 
domain
Right DNA 
binding domain
Left DNA 
binding domain
Double strand break
Donor
Homologous repair
Non homologous end joining
Figure 4  Gene editing using Zinc finger nucleases. A: Schematic showing 
a zinc finger nuclease (ZFN) dimer bound to its target locus to introduce a site-
specific double-stranded break (DSB) in the chromosome, each ZFN monomer 
consists of three to six zinc finger domains fused to the DNA-cleavage domain 
of the FokI endonuclease. B: The DNA DSB can be repaired via either the ho-
mologous recombination (HR), or C: the non-homologous end-joining pathway. 
HR requires a homologous DNA template to accurately repair DSBs in the chro-
mosome, and ensures high fidelity DNA repair. In contrast, non-homologous 
end joining does not rely on sequence homology between the DNA ends for 
ligation and can be error-prone. 
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Recent discoveries of  proteins in bacterial pathogens in 
plants have revealed new DNA binding domains: TAL 
effectors, which have tandem repeats of  amino acids that 
bind to a single base pair of  DNA. These TAL effec-
tors in conjunction with the Fok1 nuclease (TALENs) 
have been shown to function similar to ZFNs[50,51]. The 
TALEN technology provides scientists with an increase 
in modularity allowing for the creation of  many variants 
at little time and cost. Although in its infancy, this new 
technology has shown great promise; TALEN-mediated 
double-strand breaks have initiated HR at similar fre-
quencies and precision as ZFNs in human stem cells. For 
example, Hockemeyer et al[52] demonstrated the use of  
TALENs to target three endogenous loci (PPP1R12C, 
OCT4, and PITX3) in hESCs and iPSCs at efficiencies 
comparable to those reported for ZFNs for the same 
loci. TALENs have also been recently used to generate 
human stem cell-based disease models. Cowan and co-
workers reported the generation and use of  TALEN 
pairs to efficiently generate mutant alleles of  15 genes in 
human somatic and pluripotent stem cells and observed 
minimal off-target events. Further, they demonstrated 
the utility of  TALEN-mediated gene editing to develop 
detailed genotype-phenotype relationships for four genes 
known to be directly linked to various human disease 
conditions[53]. Despite these advances, further research 
is required to fully evaluate the potential of  TALENs 
before they replace ZFNs for facilitating targeted gene 
modifications in human stem cells. 
CONCLUSION AND FUTURE 
PERSPECTIVES
This review highlights the development of  two comple-
mentary approaches to efficiently modify the human 
stem cell genome. The first approach involves molecular 
engineering of  viruses, either via rational design or di-
rected evolution, to yield novel vectors that can mediate 
safe and efficient gene targeting in human stem cells. The 
second approach is the design of  custom endonucleases 
to target unique predetermined sites in the human ge-
nome and facilitate efficient homologous recombination 
with donor DNA. Each approach individually has yielded 
remarkable enhancements in gene targeting efficiencies 
and it is possible that a combination of  these comple-
mentary approaches can further enhance gene targeting. 
For example, it has recently been demonstrated that an 
evolved AAV variant can function effectively in conjunc-
tion with ZFNs to mediate highly efficient gene targeting 
(> 1%) in human pluripotent stem cells. In this study, it 
was observed that novel AAV vectors can be created to 
mediate efficient gene targeting in human pluripotent 
stem cells and in the presence of  targeted DSBs gener-
ated by the evolved AAV mediated co-delivery of  ZFNs, 
these efficiencies can be further enhanced[37]. The ob-
served enhancements in gene targeting efficiencies of  en-
gineered viral vectors in the presence of  local DSBs are 
not limited to AAV; researchers have also demonstrated 
that baculoviral and IDLV vectors can be used to co-
deliver both ZFNs and DNA donor templates to induce 
efficient gene targeting in human stem cells[54-56]. In these 
cases, researchers observed high rates of  homology di-
rected gene targeting accompanied by low frequencies of  
random chromosomal integration. 
Other strategies may explore the possibility of  com-
bining rational vector design with directed evolution - 
for example, can gene delivery efficiencies of  engineered 
AAV vectors evolved to infect human stem cells be fur-
ther improved by site-directed mutagenesis of  surface-
exposed tyrosine residues? 
In summary, the considerable progress in enhancing 
the capacity for homology directed gene targeting bear 
profound implications on basic and applied human stem 
cell research. Combining complementary approaches and 
as-of-yet unexplored possibilities offered by such strate-
gies will yield the next set of  developments in this excit-
ing and challenging field.
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